Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Summary: Background: Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Maliazurina B Saad, PhD, Lingzhi Hong, MD, Muhammad Aminu, MD, Natalie I Vokes, MD, Pingjun Chen, PhD, Morteza Salehjahromi, PhD, Kang Qin, MD, Sheeba J Sujit, PhD, Xuetao Lu, PhD, Elliana Young, MS, Qasem Al-Tashi, PhD, Rizwan Qureshi, PhD, Carol C Wu, ProfMD, Brett W Carter, ProfMD, Steven H Lin, ProfMD, Percy P Lee, ProfMD, Saumil Gandhi, MD, Joe Y Chang, ProfMD, Ruijiang Li, PhD, Michael F Gensheimer, MD, Heather A Wakelee, ProfMD, Joel W Neal, MD, Hyun-Sung Lee, MD, Chao Cheng, PhD, Vamsidhar Velcheti, ProfMD, Yanyan Lou, MD, Milena Petranovic, MD, Waree Rinsurongkawong, PhD, Xiuning Le, MD, Vadeerat Rinsurongkawong, PhD, Amy Spelman, PhD, Yasir Y Elamin, MD, Marcelo V Negrao, MD, Ferdinandos Skoulidis, MD, Carl M Gay, MD, Tina Cascone, MD, Mara B Antonoff, MD, Boris Sepesi, MD, Jeff Lewis, BS, Ignacio I Wistuba, ProfMD, John D Hazle, ProfPhD, Caroline Chung, MD, David Jaffray, ProfPhD, Don L Gibbons, ProfMD, Ara Vaporciyan, ProfMD, J Jack Lee, ProfPhD, John V Heymach, ProfMD, Jianjun Zhang, MD, Jia Wu, PhD
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-07-01
Edice:	The Lancet: Digital Health
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589750023000821
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!